Effect of the Hypericum Perforatum Extract on Serotonin Turnover in the Mouse Brain

St. John's Wort, a traditional herbal medicine obtained from the extract of Hypericum perforatum, has been used in the treatment of mild depression. Its mechanism of action remains to be established. The present study confirmed that Hypericum extract exhibited very weak inhibitory activities towards MAO. Mouse brain MAO activities was unchanged following either acute or chronic treatment with Hypericum extract. 5-HIAA levels were found to be significantly increased in the cerebral cortex, hypothalamus, hippocampus and caudate 3 h after treatment with the Hypericum extract at a dose as low as 10 mg/Kg. An increase of 5-HT levels was also observed in hypothalamus and hippocampus. The increase of brain 5-HIAA was not further enhanced following chronic administration of the herb. The Hypericum extract significantly reduced the plasma tryptophan levels, the precursor of 5-HT. The action of Hypericum extract is consistent with the notion that serotonergic system is involved. The effect of Hypericum extract on the brain 5-HIAA and 5-FIT levels appeared to be quite different from the effect of classical 5-HT re-uptake blockers.

References

• 1 Bladt S, Wagner H. Inhibition of MAO by fractions and constituents of hypericum extract.  Journal of Geriatric Psychiatry and Neurology. 1994;  7 (Suppl. 1) -59
• 2 Butterweck V, Petereit F, Winterhoff H, Nahrstedt A. Solubilized hypericin and pseudohypericin from Hypericum perforatum exert antidepressant activity in the forced swimming test.  Planta Medicine. 1998;  64 291-294
• 3 Butterweck V, Wall A, Lieflander-Wulf H, Winterhoff H, Nahrstedt A. Effects of the total extract and fractions of Hypericum perforatum in animal assays for antidepressant activity.  Pharmacopsychiatry. 1997;  30 (Suppl. 2) 117-124
• 4 Caccia S, Anelli M, Codegoni A M, Fracasso C, Garattini S. The effects of single and repeated anorectic doses of 5-hydroxytrptamine uptake inhibitors on indole levels in rat brain.  British Journal of Pharmacology. 1993;  110 355-359
• 5 Carlsson, Lindqvist M. Dependence of 5-HT and catecholamine synthesis on concentrations of precursor amino acids in rat brain.  Naunyn Sckmiedebergs Archives of Pharmacology. 1978;  303 -164
• 6 Chatterjee S S, Noldner M, Koch E, Erdelmeier C. Antidepressant activity of hypericum perforatum and hyperforin: the neglected possibility.  Pharmacopsychiatry. 1998;  31 (Suppl. 1) 7-15
• 7 Cott J M. In vitro receptor binding and enzyme inhibition by Hypericum perforatum extract.  Pharmacopsychiatry. 1997;  30 (Suppl. 2) 108-112
• 8 Dimpfel W, Schober F, Manne M. Effects of a methanolic extract and a hyperforin-enriched CO₂ extract of St. John's Wort (Hypericum perforatum) on intracerebral field potentials in the freely moving rat (Tele-Stereo-EEG).  Pharmacopsychiatry. 1998;  31 (Suppl. 1) -35
• 9 Ernst E. St. John's wort as antidepressive therapy.  Fortschrift Medicine. 1995;  113 354-355
• 10 Fernstrom J D. Role of precursor availability in control of monoamine biosynthesis in brain.  Physiology Review. 1983;  63 484-546
• 11 Friedman P A, Kappelman A H, Kaufman S. Partial purification and characterization of tryptophan hydroxylase from rabbit hindbrain.  Journal of Biological Chemistry. 1972;  247 4165-4173
• 12 Fuller R W. Role of serotonin in therapy of depression and related disorders.  Journal of Clinical Psychiatry. 1991;  52 (Suppl. 1) 52-57
• 13 Girzu M, Carnat A, Privat A M, Fialip J, Carnat A P. Sedative activity in mice of an hydroalcoholic extract of hypericum perforatum L.  Phytotherapeutical Research. 1977;  11 3956-397
• 14 Golsch S, Vocks E, Rakoski J, Nrockow K, Ring J. Reversible increase of photosensitivity by St. John's wort extract.  Hautarzt. 1997;  48 -252
• 15 Halama P. Wirksamkeit des Johanrnskrautextraktes LI 160 bei depressiver Verstimmung.  Nervenheilkunde. 1991;  10 250-253
• 16 Kaehler S T, Sinner C, Chatterjee S S, Philippu A. Hyperforin enhances the extracellular concentrations of catecholamines, serotonin and glutamate in the rat locus coeruleus.  Neurosci. Lett.. 1999;  262 -202
• 17 Laakmann G, Schule C, Baghai T, Kieser M. St. John's wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy.  Pharmacopsychiatry. 1998;  31 (Suppl 1) 54-59
• 18 Linde K, Ramirez G, Mulrow C D, Pauls A, Weidenhammer W, Melchart D. St. John's wort for depression: an overview and meta-analysis of randomized clinical trials.  British Medical Journal. 1996;  313 253-258
• 19 Lookingland K J, Shannon N J, Chapin D S, Moore K E. Exogenous tryptophan increases synthesis, storage, and intraneuronal metabolism of 5-hydroxytryptamine in the rat hypothalamus.  Journal of Neurochemistry. 1986;  47 205-212
• 20 Martinez B, Kasper S, Ruhrmann S, Moller H J. Hypericum in the treatment of seasonal affective disorders.  Journal of Geriatric Psychiatry and Neurology. 1994;  7 (Suppl. 1) -33
• 21 Muldner H, Zoller M. Antidepressive effect of a Hypericum extract standardized to an active hypericin complex; Biochemical and clinical studies.  Arzneimittelforschung. 1984;  34 918-920
• 22 Müller W E, Singer A, Wonnemann M, Hafner U, Rolli M, Schafer C. Hyperforin represents the neurotransmitter reuptake inhibiting constituent of hypericum extract.  Pharmacopsychiatry. 1998;  31 (Suppl. 1) 16-21
• 23 Müller W E, Rolli M, Schafer C, Hafner U. Effects of hypericum extract (Li 160) in biochemical models of antidepressant activity.  Pharmacopsychiatry. 1997;  30 (Suppl. 1) 102-107
• 24 Müller W E, Rossol R. Effects of hypericum extract on the expression of serotonin receptors.  Journal of Geriatric Psychiatry and Neurology. 1994;  7 (Suppl. 1) -64
• 25 Okpanyi S N, Weischer M L. Animal experiments on the psychotrophic action of a Hypericum extract.  Arzneimittelforschung. 1987;  37 10-13
• 26 Ozturk Y, Aydin S, Bei R, Baser K HC, Berberoglu H. Effects of Hypericum calycinum L. extract on the central nervous system in mice.  Phytotherpeutic Research. 1996;  10 700-702
• 27 Perovic S, Müller W EG. Pharmacological profile of Hypericum extract; Effect on serotonin uptake by postsynaptic receptor.  Arzneimittel Forschung. 1995;  45 1145-1148
• 28 Reh C, Laux P, Schenk N. Hypericum-Extrakt bei Depressionen eine wirksame Alternative.  Therapiewoche. 1992;  42 1576-1581
• 29 Schellenberg R, Sauer S, Dimpfel W. Pharmacodynamic effects of two different Hypericum extract in healthy volunteers measured by quantitative EEC.  Pharmacopsychiatry. 1998;  31 (Suppl. 1) -53
• 30 Schulz H, Jobert M. Effects of hypericum extract on the sleep EEC in older volunteers.  Journal of Geriatric Psychiatry and Neurology. 1994;  7 (Suppl. 11) -43
• 31 Simmen U, Burkard W, Berger K, Schaffner W, Lundstrom K. Extracts and constituents of Hypericum perforatum inhibit the binding of various ligands to recombinant receptors expressed with the Semliki Forest virus system.  J. Recept. Signal Transduct. Res.. 1999;  19 59-74
• 32 Teifel-Mayer R, Gleitz J. Effects of long-term administration of Hypericum extract on the affinity and density of the central serotonergic 5-HT_1A and 5-HT_2A receptors.  Pharmacopsychiaty. 1997;  30 (Suppl. 2) 113-116
• 33 Thiede H M, Walper A. Inhibition of MAO and COMT by Hypericum extract and hypericin.  Journal of Geriatric Psychiatry and Neurology. 1994;  7 (Suppl. 1) -56
• 34 Volz H P. Controlled clinical trials of Hypericum extract in depressed patients - an overview.  Pharmacopsychiatry. 1997;  30 (Suppl. 2) 72-76
• 35 Wheatley D. Hypericum in seasonal affective disorder (SAD).  Curr. Med. Res. Opin.. 1999;  15 33-37
• 36 Wheatley D. Hypericum extract- potential in the treatment of depression.  CNS Drugs. 1988;  9 431-440
• 37 Woelk H, Burkhard G, Grunwald J. Benefits and risks of the hypericum extract LI 160: drug monitoring study with 3250 patients.  Journal of Geriatric Psychiatry and Neurology. 1994;  7 (Suppl. 1) 34-38
• 38 Wong A H, Smith M, Boon H S. Herbal remedies in psychiatric practice.  Arch. Gen. Psychiat.. 1998;  55 1033-1044
• 39 Young S N. The clinical psychopharmacology of tryptophan.  Nutrition and the Brain. 1986;  7 49-88
• 40 Yu P H. Monoamine Oxidase. In: Boulton AA, Baker GB, Yu PH) (eds.) Neuromethods Volume V: Neurotransmitter Enzymes. Humana Press Clifton, New Jersey; 1986: 235-272
• 41 Yu P H, Davis B A, Durden D A, Barber, Terleckyj I, Nicklas W G, Boulton A S. Neurochemical and neuroprotective effects of some aliphatic propargylamine MAO-B inhibitors.  Journal of Neurochemistry. 1994;  62 697-704